中恒集团科创飞地落地上海 子公司蝉联高新百强

Core Insights - Zhongheng Group has achieved significant milestones in the field of traditional Chinese medicine innovation, including the establishment of the "ASEAN Traditional Chinese Medicine Research Center" in collaboration with Shanghai University of Traditional Chinese Medicine, which has been recognized as a key innovation hub in Guangxi [1][2] - The company’s subsidiary, Wuzhou Pharmaceutical, has been recognized as one of the "Top 100 High-tech Enterprises in Guangxi" for two consecutive years, highlighting its innovation capabilities and industry competitiveness [1][2] Research and Development - The ASEAN Traditional Chinese Medicine Research Center focuses on key areas such as cardiovascular diseases and tumors, with a comprehensive development path that includes new drug development and secondary development of exclusive varieties [1] - Currently, 15 projects have been initiated, including three new traditional Chinese medicine drugs for treating specific conditions and one chemical drug for atopic dermatitis [1] - The center has also launched five secondary development projects for exclusive varieties, including injectable thrombolytic agents and various health products [1] Academic and Collaborative Efforts - The center has secured funding exceeding 2 million yuan through various projects, including one national key research and development project and two Guangxi natural science fund projects [2] - Collaboration with key laboratories and universities is being strengthened, with 11 experts from Shanghai University of Traditional Chinese Medicine invited to participate in projects [2] - Wuzhou Pharmaceutical has initiated over 40 research projects, including 4 national-level and 11 regional-level projects, with 25 projects successfully completed [2]